



Millipore and Guava Technologies Team Up to Create New Solutions for Fast Growing Cell Biology Market

Companies will offer accessible, fully integrated solutions for flow cytometry

Billerica, MA and Hayward, CA- March 4, 2008- Millipore Corporation (NYSE: MIL) and Guava Technologies, Inc. today announced a long-term partnership to deliver integrated flow cytometry solutions to scientists conducting research in cell biology, including stem cell research. The companies will offer scientists superior technical performance, higher quality data, and much greater accessibility to this powerful analytical platform than is currently available.

Flow cytometry is a technique used by scientists to measure changes in protein expression in individual cells that may occur as a consequence of many important factors such as (stem) cell differentiation, disease, aging, cancer development, drug treatment, and toxicity. The combination of Millipore's and Guava's capabilities will integrate instrumentation, reagent kits, validated protocols, and technical support to bring the advantages of flow cytometry to the bench tops of cell biologists.

"Our partnership with Guava creates the potential for us to fundamentally improve the way that cell biology research is conducted," said Martin Madaus, President & CEO of Millipore. "The combination of Millipore sample prep and reagents with Guava's instrument platform will create an integrated offering, giving scientists a menu of plug and play solutions to help them generate high quality results that advance their research. The collaboration allows us to add considerable value to the highly differentiated antibody portfolio and assay development capabilities that came with our Serologicals acquisition."

Under the terms of the partnership, Millipore will gain exclusive rights to distribute Guava's non-clinical instrumentation within defined fields in North America, Europe and other countries in Asia. Additionally, Millipore will provide field service for all Guava instrumentation in the same geographies. Millipore will also develop co-branded reagent kits specifically for Guava's flow cytometers. Finally, Millipore and Guava Technologies will work together to develop a new generation of instrumentation with enhanced performance and functionality.

“Our two companies have a shared vision of making complex cellular analyses accessible to any scientist. Millipore has significant experience and reach among academic and government researchers and an extensive network of highly qualified service providers throughout the world,” said Lawrence Bruder, President and Chief Executive Officer, Guava Technologies. “With Millipore as our partner, together we can make this vision a reality and significantly increase our global presence and lower the barriers for cell biologists to adopt flow cytometry as a major research tool.”

Guava Technologies developed the first commercially-available micro-capillary flow cytometry system. Micro-capillary flow cytometers accommodate smaller sample volumes, generate less waste, have lower operating costs, and are easier to set up and run than traditional flow cytometry instrumentation. The collaboration with Millipore will now accelerate delivery of this technology directly into the hands of individual life scientists around the world.

The parties plan to launch co-branded products to the market in July 2008.

About Millipore

Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world’s challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 6,100 employees in 47 countries worldwide. For more information, please contact Millipore Tech Service at 1-800-548-7853 or 951-676-8080 or visit www.millipore.com.

ADVANCING LIFE SCIENCE TOGETHER™

Millipore Forward Looking Statement

The matters discussed herein, as well as in future oral and written statements by management of Millipore Corporation that are forward-looking statements, are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements.

Potential risks and uncertainties that could affect Millipore's future operating results with respect to the foregoing include, without limitation, weaker market acceptance of flow cytometry than we anticipate; lack of availability of raw materials or component products on a timely basis; limitations on cash flow for operations and investment due to debt service obligations; competitive factors; the inability to utilize technology in current or planned products due to overriding rights by third parties; conditions in the economy in general and in the bioscience and bioprocess markets in particular; foreign exchange fluctuations; reduced private and government research funding; and exposure to product liability claims. Please refer to our filings with the SEC,

including our most recent Annual Report on Form 10-K, for more information on these and other risks that could cause actual results to differ.

About Guava Technologies

Guava Technologies, Inc., a privately held biotechnology and medical device company, is the leading provider of on-demand, easy-to-use single cell analysis systems. Guava Personal Cell Analysis (PCA(TM)) systems, including the Guava PCA, Guava PCA-96, Guava EasyCyte Plus and Guava EasyCyte Mini systems, are integrated, fully optimized, micro-capillary cytometry systems with embedded absolute cell counting capability. Used worldwide by the life sciences, biotechnology, and pharmaceutical industries, as well as clinical testing institutions (outside the United States and Europe), Guava's products have broad applications in scientific research and throughout the drug discovery and lead optimization process, as well as for cell counting and optimization of commercial bio-pharmaceutical production. Guava offers a variety of assays and dedicated software modules for the Guava PCA systems, enhancing the system's overall ease-of-use.

More information about the company and its products is available at www.guavatechnologies.com.

Guava and Guava Technologies, Inc. are registered trademarks of Guava Technologies, Inc. EasyCyte and RapidQuant are trademarks of Guava Technologies Inc.

For Millipore media inquiries contact:

Karen Marinella Hall
Director of Corporate Communications
(978) 715-1567
karen_hall@millipore.com

For Millipore investors:

Joshua Young
Director, Investor Relations
(978) 715-1527
joshua_young@millipore.com

For Guava inquiries contact:

Marketing & Communications:
Lisa English
Communications Director
510-576-1394, lenglish@guavatechnologies.com